HCA results and 2023 guidance

 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2022.

Key fourth quarter metrics (all percentage changes compare 4Q 2022 to 4Q 2021 unless otherwise noted):

• Revenues totaled $15.497 billion

• Net income attributable to HCA Healthcare, Inc. totaled $2.081 billion, or $7.28 per diluted share

• Adjusted EBITDA totaled $3.179 billion

• Cash flows from operating activities totaled $2.527 billion

• Same facility admissions increased 2.9 percent while same facility equivalent admissions increased 5.4 percent

2023 Guidance

Today, the Company issued the following estimated guidance for 2023:

	2023 Guidance Range
Revenues	$61.5 to $63.5 billion
Net Income Attributable to HCA Healthcare, Inc.	$4.525 to $4.895 billion
Adjusted EBITDA	$11.8 to $12.4 billion
EPS (diluted)	$16.40 to $17.60 per diluted share

Capital expenditures for 2023, excluding acquisitions, are estimated to be approximately $4.3 billion.

The Company’s 2023 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding the impact of the COVID-19 pandemic as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

https://finance.yahoo.com/news/hca-healthcare-reports-fourth-quarter-120000531.html